Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Thursday

Aldeyra Therapeutics (NASDAQ:ALDX) is projected to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 3:00 PM ET.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. On average, analysts expect Aldeyra Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aldeyra Therapeutics Trading Down 5.9%

NASDAQ ALDX opened at $4.92 on Wednesday. The stock’s 50 day moving average is $5.35 and its 200 day moving average is $4.30. Aldeyra Therapeutics has a 12 month low of $1.14 and a 12 month high of $7.20. The stock has a market cap of $294.69 million, a PE ratio of -5.79 and a beta of 0.83.

Insider Activity

In other news, insider Stephen Machatha sold 22,073 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $5.15, for a total transaction of $113,675.95. Following the sale, the insider directly owned 221,799 shares of the company’s stock, valued at $1,142,264.85. This represents a 9.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.60% of the stock is owned by company insiders.

Institutional Trading of Aldeyra Therapeutics

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC raised its holdings in shares of Aldeyra Therapeutics by 275.4% during the 2nd quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock worth $5,645,000 after acquiring an additional 1,081,257 shares in the last quarter. Geode Capital Management LLC raised its holdings in Aldeyra Therapeutics by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock valued at $4,392,000 after buying an additional 8,769 shares during the period. Captrust Financial Advisors raised its holdings in Aldeyra Therapeutics by 9.1% during the 2nd quarter. Captrust Financial Advisors now owns 51,492 shares of the biotechnology company’s stock valued at $197,000 after buying an additional 4,297 shares during the period. Cerity Partners LLC purchased a new stake in Aldeyra Therapeutics during the 2nd quarter valued at $140,000. Finally, Rhumbline Advisers raised its holdings in Aldeyra Therapeutics by 2.7% during the 2nd quarter. Rhumbline Advisers now owns 77,494 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 2,018 shares during the period. 59.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Zacks Research raised Aldeyra Therapeutics to a “hold” rating in a report on Friday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aldeyra Therapeutics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Aldeyra Therapeutics has a consensus rating of “Hold” and an average price target of $9.50.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.